How could the zines be evidence for those crimes?
3,181 karma · joined April 29, 2012
How could the zines be evidence for those crimes?
This also lead to the production of specific table items intended to display celery such as the vase shown in the menus above.
I wonder if the inaccurate representation of colors by screens, etc, in any way underlies the distinctive color palette of many AI image generators?
Those that don't, or don't care, would not seek a rating, and would not be accessible to devices that parents control. Otherwise they would be free to host whatever legal content they wish.
There would obviously arise a market for a moderated, or more regulated, version of this type of social media.
Social media doesn't deserve an exemption from the efforts society makes to protect children in other domains.
Mixed content isn't a problem for broadcast TV or newspapers. They simply avoid publishing material not appropriate for children, e.g. broadcast news programs don't show gore, even when a place has been bombed and is littered with body parts.
And if they are curious about the question, it would be better if they found sources that frame the issue appropriately for their age.
Parents would be much more able to restrict the devices a child has access to (or its controls) than the websites they visit (absent website certification).
Why is it not possible to require websites that wish to market to children to be certified as "child safe". Such sites would be audited by an independent entity that would grant them some form of encrypted key. These could be in age bands, e.g. <6yr, <12 yrs, <16 yrs, etc. also also possibly geographically.
We do this for many other things, from toys to public venues.
Parents could then set their child's device to only allow access to sites with the appropriate certification.
This way the children are as safe as their parents allow them to be, without sharing their child's identity, and the rest of the population also doesn't have to share their identity with dubious authentication service or the government.
There's probably something wrong with this idea, if so I'd be glad to hear it!
I actually read your article some time ago, having found it via SSC. One comment I would make is that the pathology and genetics of AD implicate APP without much doubt. In the field, there isn't much argument against it, even by those who work on tau. Divergences in opinion more often focus on which is the better target for drug therapy.
For example, Derek Lowe's articles on AD do not argue against an APP-tau-neurodegeneration pathway (I am a regular reader of his blog), but argue that targeting amyloid is unlikely to work as a drug therapy. This argument is sometimes extended by Lowe and others to questioning whether Aβ per se is the agent that triggers the downstream effects of either mutating APP or otherwise disrupting its biology. It is possible that Aβ is a by-product of the "true" APP-triggered pathway, see the arguments in favor of C-terminal fragments I linked to earlier.
A fundamental problem the field faces is that it is difficult to experimentally induce actual AD in animals, and so it is difficult to scientifically test hypotheses as to what might cause it. Compare perhaps to something like diabetes. Exactly why mice do not develop realistic AD is unknown.
In addition, there have been literally hundreds of publications (minimum 300) claiming to reverse "Alzheimer's disease" in mice, and the only ones that have lead to any kind of meager success are those using the antibodies. The arguments made in the 2010 review below by Zahs and Ashe [0] remain mostly true sixteen years later.
The recent clinical trials, e.g. Lecanemab, are of interest not only because they might provide at least some benefit, but also because they might represent the first actual scientific experiments showing that removing Aβ can ameliorate the disease, even if only slightly because of the late stage at which they have so far been tested.
Currently ongoing trials using anti-Aβ antibodies and targeting earlier phases of the disease in those with inherited mutations are of keen interest. If these demonstrate clear prevention of disease progression, then the Aβ hypothesis can be considered tested and proven. If not, then the Aβ hypothesis should be abandoned. This would however still not disprove an APP-focused hypothesis.
[0] 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? https://alzped.nia.nih.gov/sites/default/files/2022-09/zahs....
As you have demonstrated an interest in this topic, but are not an active researcher, I suggest that you become familiar with Alzforum [www.alzforum.org]. It provides reputable summaries and comments from leading researchers on topical issues and papers in Alzheimer's and related neurodegenerative diseases.
They're still fairly technical, but not as dense as the original papers. Here is an example related to our discussion: https://www.alzforum.org/news/research-news/app-c-terminal-f...
This is why researchers now most often use the 5XFAD mouse, which has APP with three mutations, and presenilin with two mutations (hence 5 FAD mutations) [0]. Note however that mutated presenilin alone is enough to cause neurodegeneration in mice, such mice however do not accumulate amyloid, which is why mutated APP in added to make the pathology more "realistic".
As to Aβ42, there are mutations in APP which cause familial AD, but produce exclusively Aβ40, e.g. APP A673V [1]. Note also that most studies report alterations in the ratio of Aβ42 to Aβ40, precisely because effects on the levels of Aβ production are inconsistent across APP mutations.
Nevertheless..... and despite my obvious skepticism towards the amyloid toxicity hypothesis, the mutations in APP that cause AD all cluster in or near the region of the protein that is Aβ. There must be a reason for that. It is also in contrast to presenilin, where the mutations are distributed throughout the molecule, indication a loss of presenilin function causes AD.
One alternate explanation to Aβ or oligomer toxicity is proposed toxicity of the immediate precursor to Aβ, i.e. the APP C-terminal fragment (CTF), see for example the recent paper below and references therein [2].
[0] https://www.alzforum.org/research-models/5xfad-b6sjl
[1] A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis https://pmc.ncbi.nlm.nih.gov/articles/PMC2728497/
[2] APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ https://pmc.ncbi.nlm.nih.gov/articles/PMC12017768/
Note that not all AD-causing mutations in APP also cause amyloid accumulation, for example APP-Osaka (loss of APP residue E693) results in familial AD without any accumulation of amyloid [0]. (One can ignore claims that this mutation increases Abeta oligomers, since the evidence is that Abeta oligomers are found at far too low concentrations in the human brain. They would have to be more toxic than ricin if they were etiological for AD). The oligomers seen on gels are an artefact, see the controversy surrounding Tessier-Lavigne).
As you state, and I agree, APP is upstream of tau in natural AD pathogenesis, but does not cause neurodegeneration in mice. So we still don't know from direct experimentation how APP leads to tauopathy and neuodegeneration. The evidence that this is through Abeta per se is tentative at best.
[0] A Second Pedigree with Amyloid-less Familial Alzheimer’s Disease Harboring an Identical Mutation in the Amyloid Precursor Protein Gene (E693delta) https://pubmed.ncbi.nlm.nih.gov/25743013/
So, taking the amyloid hypothesis itself (putting presenilin aside for the time being).
We know that mutations in APP do cause AD. How? And if amyloid is not the "proximate" cause of AD, how do mutations in APP cause AD? Include in this Down syndrome, where >90% of cases develop early onset AD by age 50. They have an extra copy of APP that is not mutated.
Furthermore, people can accumulate large amounts of amyloid in the brain without having any notable dementia.
Adding tau to the equation does not help much in explaining how APP mutations cause AD. All people have tau. Furthermore, mutations in tau do not cause AD, they cause different neurodegenerative diseases (e.g. frontotemporal dementia).
Combining APP mutations with presenilin mutation and/or tau mutations in mice does lead to worse outcomes, but the same could be said for combining any other random set of neurodegeneration-associated gene mutations.
One may then ask, what is being remedied in the many, many, studies that claim to successfully target amyloid toxicity in mice? And is this relevant to the processes that occur in AD?
Human pathology studies are limited in ability to determine causal agents because they are primarily observational, i.e. they find correlations, show that changes in certain other proteins or processes are associated, such as tau that you mention, inflammation, etc. Or as you mention, show that the pathological hallmarks of AD have a stereotypical order of appearance.
However, the only human studies that can demonstrate cause in AD are genetic studies.
The strength of the amyloid hypothesis is that it is currently the only way to unify early onset AD that is caused by mutations in APP and presenilin with the pathology of both early and late set AD.
The weakness is that experimental mice expressing mutated APP do not get neurodegeneration, despite showing amyloid accumulation and behavioral defects.
Mice expressing mutated presenilin in contrast do get both behavioral defects and neurodegeneration, despite showing no accumulation of amyloid.
"Perhaps mice are different" is the usual response/excuse.
This defense is considerably weaker now, given the very modest benefits of removing amyloid from the human brain, as shown in recent clinical trials.
So.... when considered rigorously, the amyloid hypothesis remains to be proven.
However, it will always have its supporters until there is an alternate explation for the convergence of mutations in APP and presenilin on precisely that region of APP that generates amyloid.
It perhaps isn't too different from LLMs being able to coherently output short, a few hundred words, pieces of prose, or code, but not being able to assemble them into functional output with constant "nudging".
Happy to be corrected on this!
tl;dr, the higher cognitive abilities of birds are centered in a different region of the brain compared to mammals, the pallium vs the cortex. Neuron density in the bird pallium is also higher than the comparable density in the mammalian cortex.
[0] Developmental origins and evolution of pallial cell types and structures in birds https://www.science.org/doi/10.1126/science.adp5182
Also, the Vatican is the Holy See (as in seat), not Holy Sea (as in water)...
What is dominating the thread are claims that the LLM operation in question is analogous to the function of sleep in humans. It obviously is not.
The anthropomorphization of LLMs has reached ridiculous proportions. Applying the same standards as used in this field to others would result in claims that laundry machines "hallucinated" that they had had sufficient water when they failed due to the faucet being turned off.
It's still weak, though. An LLM without constant human input is likely more similar to a bicycle that starts to lose its gyroscopic balance as it moves more slowly, a human can however keep a stationary bicycle upright (while riding it).